MedTrace Logo

Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy

NCT01895400 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2016-02-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether Renexin is effective in the treatment of vestibular symptoms in patients with recurrent vestibulopathy.

Conditions

  • Recurrent Vestibulopathy

Interventions

DRUG

Renexin (cilostazol 100mg + gingko biloba extract 80 mg)

Take Renexin 1T bid po medication for 8 weeks

DRUG

Placebo

Take placebo drug 1T bid po medication for 8 weeks

Sponsors & Collaborators

  • SK Chemicals Co., Ltd.

    collaborator INDUSTRY

  • Asan Medical Center

    collaborator OTHER

  • Jong Woo Chung

    lead OTHER

Principal Investigators

  • Jong Woo Chung, MD · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01895400 on ClinicalTrials.gov